Vertex Solutions, a small business known for the manufacturing of systems integration and advanced training technologies, has ...

In a report released today, Chris Quintero from Morgan Stanley maintained a Buy rating on Vertex (VERX – Research Report), with a price target ...

DA Davidson lowered the firm’s price target on Vertex (VERX) to $50 from $55 and keeps a Buy rating on the shares as part of a broader research ...

Ratings for Vertex VERX were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

SINGAPORE & MONTREAL — Vertex Growth, a Singapore-based growth-stage venture capital fund, today announced a commitment of €10M in Dolphin Semiconductor, a leading provider of semiconductor IP ...

Google Cloud’s latest enhancements to Vertex AI and the Gemini model family offer businesses a comprehensive solution for building, deploying, and managing AI applications with unprecedented ...

But NICE rejected Vertex’s CF latest drug Orkambi for routine NHS funding in final guidance published in July 2016, saying the drug’s £104,000 per year price tag was too expensive.

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner ...

KING OF PRUSSIA, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release first ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...